UPS patients have poor outcomes in comparison to other sarcoma patients treated with radiotherapy and surgery.4,21 In this patient population with a clinically unmet need, our study supports the investigation of immunotherapy agents targeting the costimulatory molecules 4–1BB and OX40. Here, TNFRSF4 is linked to undifferentiated pleomorphic sarcoma.